|
Characteristics
|
Ruxolitinib is a potent and selective Janus kinase (JAK) inhibitor with with IC50's of 2.7 and 4.5 nM for JAK1 and JAK2, respectively. Displays clinically significant activity in myelofibrosis.
Synonyms: INCB018424, INC18424, NCB018424, NCB18424
|
